Skip to content
Men Under Microscope – Lifestyle
Author:
Spero Therapeutics, Inc.
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
July 27, 2026
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
July 14, 2026
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
July 14, 2026
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
June 17, 2026
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update
May 13, 2026
←
Previous Page
1
2